Leukaemia - acute myeloid leukaemia

The PBS subsidises midostaurin for patients with acute myeloid leukaemia (AML).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with midostaurin under the National Health Act 1953, section 100 for patients with AML.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing midostaurin.

Section 100 arrangements

Midostaurin

This item is only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn't PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for induction and consolidation treatment

Apply for induction and consolidation treatment with PBS subsidised midostaurin for AML either:

Applying for initial maintenance treatment

Apply for initial maintenance authority approval to prescribe PBS subsidised midostaurin to treat AML in writing by either:

All applications must include the completed:

Applying for continuing maintenance treatment

Apply for continuing maintenance authority approval to prescribe PBS subsidised midostaurin to treat AML by either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 June 2021